ALNY
What one share of Alnylam Pharmaceuticals holds
Pharmaceutical Preparations
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi.
Alnylam Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $34.63 |
|---|---|
| Profit | $5.58 |
| Capex (buildings and equipment) | $0.66 |
| Free cash flow | $5.91 |
| Cash and investments | $12.77 |
| Book value | $10.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.55 | −$4.79 | $0.75 | −$4.35 | — | $10.71 |
| 2017 | $0.99 | −$5.42 | $1.15 | −$5.38 | — | $17.72 |
| 2018 | $0.74 | −$7.57 | $1.26 | −$6.85 | — | $12.87 |
| 2019 | $2.01 | −$8.11 | $1.28 | −$3.83 | — | $12.82 |
| 2020 | $4.29 | −$7.46 | $0.61 | −$5.96 | — | $8.73 |
| 2021 | $7.13 | −$7.20 | $0.64 | −$6.06 | — | $4.89 |
| 2022 | $8.53 | −$9.30 | $0.59 | −$5.04 | — | −$1.28 |
| 2023 | $14.64 | −$3.52 | $0.50 | $0.34 | — | −$1.75 |
| 2024 | $17.61 | −$2.18 | $0.27 | −$0.33 | — | $0.52 |
| 2025 | $27.58 | $2.33 | $0.44 | $3.46 | — | $5.96 |